DA 6650

Drug Profile

DA 6650

Alternative Names: DA-6650

Latest Information Update: 22 Aug 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dong-A Pharmaceutical
  • Class Anti-inflammatories; Benzamides; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Dyspepsia; Gastro-oesophageal reflux; Irritable bowel syndrome

Most Recent Events

  • 06 Nov 2011 No development reported - Phase-I for Dyspepsia in South Korea (PO)
  • 06 Nov 2011 No development reported - Phase-I for Gastro-oesophageal reflux in South Korea (PO)
  • 06 Nov 2011 No development reported - Phase-I for Irritable bowel syndrome in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top